MGNX earnings

First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC, expected in second half of 2025 Advancement in portfolio of innovative ADC product candidates, including MGC026, MGC028 and MGC030 Cash, cash equivalents and marketable securities of $154.1 million as of March 31, 2025 ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for

ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025.  The Company will not be hosting a conference call to discuss its financial results or corporate progress for the quarter ended March 31, 2025. The Company may resume its practice of hosting quarterly results conference calls in the future. About MacroGenics, Inc.MacroGenics (the Company) is a biopharm

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030Discontinuing further internal clinical development of vobra duo; exploring potential partneringCash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway extended into the second half of 2026Conference call scheduled for today at 4:30 p.m. ET  ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical com

ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday, March 20, 2025. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March 20, 2025, at 4:30 pm ET Conference Call Information To participate via telephone, please register in advance via this link. Upon registration, all telephone part

Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte related to advancement of ZYNYZ®ADAM9-directed ADC (MGC028) Investigational New Drug (IND) application submitted to FDA Conference call scheduled for today at 4:30 p.m. ET  ROCKVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 

ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2024 after the market closes on Tuesday, November 5, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, November 5, 2024, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance via this link. Upon registration, all telephone participants will receive a

Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing an extension of treatment duration as compared to Phase 1 mCRPC dose expansion cohortCompany expects to have mature median rPFS no later than early 2025MacroGenics to host an investor call to review key data presented at ESMO and provide a general corporate update on Monday, September 16, 2024, at 8:00 a.m. ET ROCKVILLE, MD, Sept. 15, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing

ROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced a poster presentation relating to Phase 2 data of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain from September 13-17, 2024. The following poster will be available on Sunday, September 15, 2024: TAMARACK: Randomized Phase 2 trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitam

Upcoming poster presentation of protocol-defined TAMARACK Phase 2 mCRPC study data at ESMO in SeptemberReceived $100.0 million in milestones related to Incyte's advancement of ZYNYZ® (retifanlimab-dlwr) subsequent to quarter-endConfirming cash runway guidance into 2026 ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2024. "We are pleased to have the opportunity to present

Abstract of clinical data accepted for poster presentation at ESMO Congress 2024 in SeptemberESMO poster to include protocol-defined TAMARACK Phase 2 mCRPC study data, including pre-defined landmark primary endpoint of 6-month rPFS rate and updated safetyTreatment recently discontinued for TAMARACK mCRPC study participants who remained eligible for further dosing following review of totality of data, including efficacy, and emerging adverse events associated with prolonged exposure and considering potential risk/benefit to participants; most had received at least 8 cycles of vobra duoGiven embargoed TAMARACK data presentation at ESMO, Company plans to host an investor update call following E

Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2024. "We are very encouraged by the interim updated safety and preliminary efficacy data from the TAMARACK study of vobra duo in metastatic castration-

ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, May 9, 2024, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a c

Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I inhibitor-based ADCPreclinical data on two topoisomerase I inhibitor-based ADC product candidates, MGC026 and MGC028, to be presented in posters at AACRConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progres

ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2023 after the market closes on Thursday, March 7, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March 7, 2024, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive

Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of scheduleInitiated LORIKEET Phase 2 study of lorigerlimab Submitted IND for MGC026, a topoisomerase inhibitor-based ADC Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2023. "Since mid-2022, we have received $335 million in non-dilutive capital from our coll

ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2023 after the market closes on Monday, November 6, 2023. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Monday, November 6, 2023, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receiv

Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol Initiating lorigerlimab Phase 2 study in mCRPC patients Achieved $50 million milestone related to Sanofi's announcement of positive top-line data from TZIELD® (teplizumab-mzwv) type 1 diabetes study Conference call scheduled for today at 4:30 p.m. ET  ROCKVILLE, Md., Aug. 09, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for t

ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter of 2023 after the market closes on Wednesday, August 9, 2023. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Wednesday, August 9, 2023, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance via this link. Upon registration, all telephone participants

ZYNYZ™ is third product approved in U.S. that originated from MacroGenics' pipelineMultiple Phase 2 programs advancing in metastatic castration-resistant prostate cancer (mCRPC)Cash runway through 2025 with $270 million in non-dilutive funding achieved over past nine monthsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2023. "The recent U.S. Food a

ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2023 after the market closes on Tuesday, May 9, 2023. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, May 9, 2023, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance via this link. Upon registration, all telephone participants will receive a confirmation em

Cash runway extended through 2025 with $250 million in non-dilutive funding over past eight months TAMARACK study design modified with objective of accelerating data readoutEncouraging lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) monotherapy clinical data presented at ASCO-GUConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., March 15, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2022. "Our rece

ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2022 after the market closes on Wednesday, March 15, 2023.  MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Wednesday, March 15, 2023, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive

Collaboration with Gilead to develop bispecific antibodies, including MGD024, announced Planned initiation of Phase 2 portion of MGC018 TAMARACK study in prostate cancer by year-endAnticipated update on lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) monotherapy clinical data in first quarter of 2023Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended Septe

ROCKVILLE, MD, Oct. 26, 2022 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2022 after the market closes on Thursday, November 3, 2022.  MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, November 3, 2022, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance via this link. Upon registration, all telephone participants will receive a

First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignanciesPlan to initiate MGC018 Phase 2/3 study in prostate cancer by year-endInitiates cost-saving measures through corporate restructuring with focus on key clinical programs, extending cash runway into 2024 with goal of delivering value-creating data milestones$30 million milestone payments received in July from Incyte as part of collaboration agreementConference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treat

ROCKVILLE, MD, July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter of 2022 after the market closes on Monday, August 8, 2022.  MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Monday, August 8, 2022, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirma

Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumorsTargeting mid-2022 start of Phase 1 study of MGD024 in hematologic malignanciesConference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2022. "We are very pleased by the progress made during the fi

ROCKVILLE, MD, April 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter 2022 after the market closes on Tuesday, May 3, 2022.  MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, May 3, 2022, at 4:30 pm ET. The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the Conferenc

Initiating Phase 1 dose escalation study of MGC018 in combination with lorigerlimab (formerly MGD019) in coming weeksPrioritizing MGD024 as lead CD3-based DART® molecule targeting CD123 and discontinuing development of flotetuzumabPresented encouraging preclinical combinatorial anti-tumor activity with MGD024 at ASH in DecemberConference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for

ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2021 after the market closes on Thursday, February 24, 2022.  MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, February 24, 2022, at 4:30 pm ET. The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and provid

Investigational New Drug (IND) application submitted for MGD024, a next generation DART® molecule targeting CD123 and CD3 for AMLU.S. Food & Drug Administration (FDA) approves MacroGenics' GMP manufacturing facility to produce MARGENZA® drug substance Discontinuing enrollment of Cohort A of Phase 2/3 MAHOGANY study of margetuximab Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financi

ROCKVILLE, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2021 after the market closes on Tuesday, November 2, 2021.  MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, November 2, 2021 at 4:30 pm ET. The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing th

Upcoming MGC018 and margetuximab MAHOGANY clinical data presentations at European Society for Medical Oncology (ESMO) MeetingConference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md., July 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2021. "In June, we presented encouraging data from a Phase 1 study of MGC018 at ASCO. We look forward to providing further updates on this compound and ma

ROCKVILLE, MD, July 22, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter 2021 after the market closes on Thursday, July 29, 2021. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, July 29, 2021 at 4:30 pm ET. The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the Co